A retrospective study on 529 pancreatic cancer patients after neoadjuvant therapy reveals adjuvant therapy’s survival benefit. For the entire cohort, no significant overall survival difference was observed. However, subgroup analysis shows a survival advantage with adjuvant therapy for those with less than 4 months of neoadjuvant treatment or microscopic margin positive surgical resections. This insight underscores the nuanced impact of adjuvant therapy in specific pancreatic cancer patient subsets.
Journal Article by Shimizu T, Maeda S (…) Donahue T et 16 al. in BMC Surg
Copyright © 2024 Elsevier Inc. All rights reserved.